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THROMBOLYSIS OF THROMBOSED ST. JUDE MEDICAL PROSTHETIC VALVES:
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Prosthetic valve thrombosis is one of the most frequent
complications after valve replacement surgery. A second
surgical procedure with debridement or replacement of
the valve (or both) has been the traditional method of
management,1 with systemic thrombolysis lingering as an
alternative for more than two decades.2 The mortality
with second valve replacement has been relatively high
(20%).3 With systemic thrombolysis the mortality is lower
(0% to 10%)2, 4, 5 but is associated with embolic compli-
cations that are usually without permanent sequelae.
Rethrombosis occurs in 20% of patients after successful
thrombolysis.5 A repeat thrombolysis has been advocated
for patients with rethrombosis.5
Results of systemic thrombolysis in 10 patients receiving
tissue plasminogen activator (TPA) for thrombosis of a
left-sided St. Jude Medical valve (St. Jude Medical, Inc.,
St. Paul, Minn.) are presented here with a focus on the
mid-term follow-up and the management of rethrombosis.
The clinical data and the follow-up of 10 consecutive
patients are summarized in Table I. The international
normalized ratio on admission was within the therapeutic
range in only three of the 10 patients. The diagnosis was
established and the treatment was monitored by cinefluo-
roscopy. TPA was administered as a bolus of 10 mg
followed by an infusion of 5 mg/hr. When full valve
mobility was achieved, TPA was stopped and a continuous
infusion of heparin was commenced. At the same time
warfarin was introduced, and when the therapeutic range
of anticoagulation was achieved heparin was discontinued.
Successful thrombolysis was achieved in nine of 10
patients (Table II). A total dose of 100 mg of TPA
established satisfactory thrombolysis in 11 of the 13
treatments given.
In two patients complications developed that could be
attributed to the administration of TPA. One patient had
pelvic bleeding related to a recent gynecologic infection
and was successfully treated medically. The second patient
had an episode of epistaxis.
During follow-up, one patient who had successful
thrombolysis died in a peripheral hospital with clinical
signs of rethrombosis 2 weeks after discharge. He had not
received therapeutic levels of anticoagulants. Three pa-
tients were found to have poor valve mobility, and a
second course of TPA was administered. The second
thrombolysis resulted in good valve mobility. All three
patients with a second course of TPA returned with
evidence of valve dysfunction as documented by limited
leaflet mobility. Two of them were subjected to surgery,
and evidence of tissue ingrowth involving the hinge points
of the valves was found, similar to that in the patient who
was operated on after an unsuccessful first course of
thrombolysis.
Comparative data concerning the choice of thrombo-
lytic agents are not available. We believe that the present
group of 10 patients treated with TPA is the largest
reported yet for this agent. The comparison of our results
with those of Vitale and coworkers4 suggests that the
method of administration (a long-term infusion versus an
accelerated administration) is probably not significant.
Rethrombosis was more prevalent in our patients than in
those from other reports.2, 4, 5 Of the five patients with a
rethrombosis and/or unsuccessful thrombolysis, one died
in a peripheral hospital as a result of inadequate antico-
agulation and three others were subjected to a second
valve replacement. Evidence of tissue ingrowth in these
three patients raises the question of whether surgical
treatment, without a second course of thrombolytic
agents, should be pursued immediately in patients having
rethrombosis or valve dysfunction after a successful
thrombolytic treatment. To this end, a retrospective blind
reassessment of valve mobility in our patients was con-
ducted and failed to demonstrate differences between
patients in whom the tissue ingrowth was an important
factor. We believe that tissue ingrowth was the cause of
rethrombosis and not a failure of primary thrombolysis.
The results of reoperation and systemic thrombolysis
are probably comparable,1-5 although no randomized
study has compared them. Vitale and associates4 used
thrombolysis in eight patients with a short duration of
symptoms and with preserved movement of a disc or
leaflet and found a very good mid-term results. Another
group of 20 patients was submitted to an emergency
reoperation, and tissue ingrowth was found in 65% of
them; that is, another seven patients could have profited
from thrombolysis.4 The definition of reliable echocardio-
graphic criteria of the type of thrombosis (i.e., thrombus
only or an apposition of thrombus on preexisting tissue
ingrowth) by transthoracic or transesophageal echocardi-
ography is necessary to allow an appropriate selection of
patients for either method.
Systemic thrombolysis is an additive rather than a
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competitive method for the treatment of patients with
thrombosed left-sided prosthetic valves. Present results
confirm that tissue ingrowth is a frequent cause of re-
thrombosis and suggests that patients with a recurrence of
thrombosis should be submitted to a second operation
rather than to a second course of thrombolysis.
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Table I. Clinical data of patients
Patient
No.
Age
(yr) Sex
Months from
operation Symptoms Valve affected
History of poor
compliance
Patients with good long-term result
1 13 Male 3† Asymptomatic‡ MVR Poor compliance
2 43 Female 4 Asymptomatic‡ MVR Warfarin defaulted
3* 22 Female 103 Asymptomatic‡ AVR Warfarin defaulted
4 50 Male 13 Chest pain MVR No
5 16 Male 35 Pyrexia§ MVR No
Patients without satisfactory long-term results
6 11 Male 29 Dyspnea AVR, MVR Poor compliance
7* 39 Female 29 Dyspnea, weakness AVR, MVR Warfarin defaulted
8 45 Male 75 TIA MVR No
9 16 Female 8 Dyspnea MVR No
10 13 Male 48 CCF MVR Warfarin defaulted
MVR, Mitral valve replacement; AVR, aortic valve replacement; TIA, repeat transient cerebrovascular accidents documented as infarctions on computed
tomographic scan; CCF, congestive cardiac failure lasting for a few months before presentation.
*Patient was pregnant at the time of dysfunction.
†Patient underwent two previous reoperations for thrombosed mitral valve.
‡Clinical suspicion was based on a new murmur.
§Corynebacterium sepsis.
Table II. Follow-up of patients
Patient
No.
Follow-up
(mo)
Repeat
thrombolysis
(mo)
Operation
(mo from first
thrombolysis)
Findings during
operation Final result
Patients with good long-term result
1 36 No No — Asymptomatic; normal leaflets mobility
2 28 No No — Asymptomatic; normal leaflets mobility
3 24 No No — Asymptomatic; normal leaflets mobility;
repeat pregnancy
4 20 No No — Asymptomatic; normal leaflets mobility
5 28 No No — Asymptomatic; normal leaflets mobility
Patients without satisfactory result
6 0.5 No No — Died two weeks after thrombolysis;
poor anticoagulation
7 51 Yes (7) Yes (24) Clot; tissue
ingrowth
Asymptomatic; normal function of both
prosthetic valves
8 30 Yes (2) No — Asymptomatic; persistent limitation of
leaflets mobility*
9 21 Yes (3) Yes (19) Tissue ingrowth Asymptomatic; normal MVR function
10 9 No
(primary
failure)
Yes (immediately) Tissue ingrowth Asymptomatic, normal MVR function;
defaulted follow-up
MVR, Mitral valve replacement.
*Patient has experienced no symptoms after second thrombolysis and has not been compliant to any further procedure.
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